The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial

INTRODUCTION: The aim of this investigation was to assess the effect of galantamine, an acetylcholinesterase inhibitor and allosteric modulator of nicotinic receptors, on brain atrophy in individuals with mild cognitive impairment (MCI), and to assess effect modification by apolipoprotein E (APOE) g...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Alzheimers Res Ther
Autors principals: Prins, Niels D, van der Flier, Wiesje A, Knol, Dirk L, Fox, Nick C, Brashear, H Robert, Nye, Jeffrey S, Barkhof, Frederik, Scheltens, Philip
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2014
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4255389/
https://ncbi.nlm.nih.gov/pubmed/25478019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/alzrt275
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars